Maturitas
Volume 57, Issue 1 , Pages 6-10 , 20 May 2007

WHI risks: Any relevance to menopause management?

References 

  1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in health postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  2. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2004;291:1701–1712
  3. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453–461
  4. Williams JK, Anthony MS, Honoré EK. Regression of atherosclerosis in female monkeys. Arterioscler Thomb Vasc Biol. 1995;15:827–836
  5. Manson JE, Hsia J, Johnson KC, et al. For the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523–534
  6. Naftolin F, Taylor HS, Karas RH, et al. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril. 2004;81:1498–1501
  7. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: The Women's Health Initiative. Arch Intern Med. 2006;166:357–365
  8. Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy early postmenopausal women. Arch Intern Med. 2004;164:482–484
  9. Chlebowski RT, Hendrix SL, Langer RD, et al. For the WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA. 2003;289:3243–3253
  10. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas. 2006;55:103–115
  11. Kuhl H. Is the elevated breast cancer risk observed in the WHI study an artefact?. Climacteric. 2004;7:319–323
  12. Burger HG. Hormone therapy in the WHI era. ANZCOG. 2006;46:84–91
  13. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer, hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologic studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet. 1997;350:1047–1059[erratum in: Lancet 1997;350:1484]
  14. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med. 2006;166:1027–1032
  15. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol. 2006;180:1354–1360
  16. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med. 2006;166:722–780
  17. Shumaker SA, Legault C, Thal L, et al. For the WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651–2662
  18. Zandi PP, Carlson MC, Plassman BL, et al. For the Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 2002;288:2123–2129

PII: S0378-5122(07)00062-X

doi: 10.1016/j.maturitas.2007.02.002

Maturitas
Volume 57, Issue 1 , Pages 6-10 , 20 May 2007

Article Tools